Can we count your visit with Google Analytics? No ads, no profiles. Details
NVAX
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: post-pandemic biotech transitioning from in-house COVID vaccine commercialization to a royalty + milestone model after the May 2024 $SNY (Sanofi) co-exclusive license for Nuvaxovid ($500M upfront, up to $700M development/launch/sales milestones, mid-teens to high-teens royalties, plus separate Matrix-M adjuvant licensing economics on Sanofi pipeline use).
Pipeline pivots to a standalone flu vaccine (Phase 3 readout expected) and a flu/COVID combination, with the Matrix-M adjuvant as a partnership-grade platform asset.
It reads our $NVAX data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.